Probiotic bacteria enhance murine and human intestinal epithelial barrier function
Background & Aims: The probiotic compound, VSL#3, is efficacious as maintenance therapy in pouchitis and ulcerative colitis. The aim of this study was to determine the efficacy of VSL#3 as a primary therapy in the treatment of colitis in the interleukin (IL)-10 gene-deficient mouse. Mechanisms o...
Gespeichert in:
Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2001-09, Vol.121 (3), p.580-591 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 591 |
---|---|
container_issue | 3 |
container_start_page | 580 |
container_title | Gastroenterology (New York, N.Y. 1943) |
container_volume | 121 |
creator | Madsen, Karen Cornish, Anthony Soper, Paul McKaigney, Conor Jijon, Humberto Yachimec, Christine Doyle, Jason Jewell, Lawrence De Simone, Claudio |
description | Background & Aims: The probiotic compound, VSL#3, is efficacious as maintenance therapy in pouchitis and ulcerative colitis. The aim of this study was to determine the efficacy of VSL#3 as a primary therapy in the treatment of colitis in the interleukin (IL)-10 gene-deficient mouse. Mechanisms of action of VSL#3 were investigated in T84 monolayers. Methods: IL-10 gene-deficient and control mice received 2.8 × 108 colony-forming units per day of VSL#3 for 4 weeks. Colons were removed and analyzed for cytokine production, epithelial barrier function, and inflammation. VSL#3 or conditioned media was applied directly to T84 monolayers. Results: Treatment of IL-10 gene-deficient mice with VSL#3 resulted in normalization of colonic physiologic function and barrier integrity in conjunction with a reduction in mucosal secretion of tumor necrosis factor α and interferon γ and an improvement in histologic disease. In vitro studies showed that epithelial barrier function and resistance to Salmonella invasion could be enhanced by exposure to a proteinaceous soluble factor secreted by the bacteria found in the VSL#3 compound. Conclusions: Oral administration of VSL#3 was effective as primary therapy in IL-10 gene-deficient mice, and had a direct effect on epithelial barrier function.
GASTROENTEROLOGY 2001;121:580-591 |
doi_str_mv | 10.1053/gast.2001.27224 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71150468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016508501903269</els_id><sourcerecordid>71150468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-79013f82964553dfe4708d9a81a38ff965562b8c1f64707ee8fc9857aebc4e1a3</originalsourceid><addsrcrecordid>eNp1kE1PwzAMQCMEYmNw5oZ6QNy6JWnTpEc08SVNAiE4R2nqsKA2HUmKxL8nY5PgwsmW_WzZD6FzgucEs2LxpkKcU4zJnHJKywM0JYyKPBXoIZqmUOUMCzZBJyG8Y4zrQpBjNCGJorykU_T85IfGDtHqrFE6grcqA7dWTkPWj946yJRrs_XYK5dZFyFE61SXwcbGNXQ2pY3y3oLPzOh0tIM7RUdGdQHO9nGGXm9vXpb3-erx7mF5vcp1yeuY8xqTwghaVyVjRWug5Fi0tRJEFcKYumKsoo3QxFSpwwGE0bVgXEGjS0jQDF3t9m788DGmw2Rvg4auUw6GMUievsRlJRK42IHaDyF4MHLjba_8lyRYbjXKrUa51Sh_NKaJi_3qsemh_eX33hJwuQdU0KozPgmz4Q9XUCJ4wuodBsnDZ5Ikg7aQ3LbWg46yHey_N3wDdmqOxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71150468</pqid></control><display><type>article</type><title>Probiotic bacteria enhance murine and human intestinal epithelial barrier function</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Madsen, Karen ; Cornish, Anthony ; Soper, Paul ; McKaigney, Conor ; Jijon, Humberto ; Yachimec, Christine ; Doyle, Jason ; Jewell, Lawrence ; De Simone, Claudio</creator><creatorcontrib>Madsen, Karen ; Cornish, Anthony ; Soper, Paul ; McKaigney, Conor ; Jijon, Humberto ; Yachimec, Christine ; Doyle, Jason ; Jewell, Lawrence ; De Simone, Claudio</creatorcontrib><description>Background & Aims: The probiotic compound, VSL#3, is efficacious as maintenance therapy in pouchitis and ulcerative colitis. The aim of this study was to determine the efficacy of VSL#3 as a primary therapy in the treatment of colitis in the interleukin (IL)-10 gene-deficient mouse. Mechanisms of action of VSL#3 were investigated in T84 monolayers. Methods: IL-10 gene-deficient and control mice received 2.8 × 108 colony-forming units per day of VSL#3 for 4 weeks. Colons were removed and analyzed for cytokine production, epithelial barrier function, and inflammation. VSL#3 or conditioned media was applied directly to T84 monolayers. Results: Treatment of IL-10 gene-deficient mice with VSL#3 resulted in normalization of colonic physiologic function and barrier integrity in conjunction with a reduction in mucosal secretion of tumor necrosis factor α and interferon γ and an improvement in histologic disease. In vitro studies showed that epithelial barrier function and resistance to Salmonella invasion could be enhanced by exposure to a proteinaceous soluble factor secreted by the bacteria found in the VSL#3 compound. Conclusions: Oral administration of VSL#3 was effective as primary therapy in IL-10 gene-deficient mice, and had a direct effect on epithelial barrier function.
GASTROENTEROLOGY 2001;121:580-591</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1053/gast.2001.27224</identifier><identifier>PMID: 11522742</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Bifidobacterium ; Biological and medical sciences ; Cell Line ; Colitis - metabolism ; Colitis - therapy ; Digestive system ; Epithelial Cells - metabolism ; Epithelial Cells - microbiology ; Humans ; Interleukin-10 - genetics ; Interleukin-8 - metabolism ; Intestinal Absorption - physiology ; Intestinal Mucosa - cytology ; Intestinal Mucosa - metabolism ; Intestinal Mucosa - microbiology ; Lactobacillus ; Medical sciences ; Mice ; Mice, Inbred Strains ; Mice, Knockout ; Patch-Clamp Techniques ; Pharmacology. Drug treatments ; Probiotics - pharmacology ; Salmonella Infections - prevention & control ; Salmonella Infections - therapy ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 2001-09, Vol.121 (3), p.580-591</ispartof><rights>2001 American Gastroenterological Association</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-79013f82964553dfe4708d9a81a38ff965562b8c1f64707ee8fc9857aebc4e1a3</citedby><cites>FETCH-LOGICAL-c479t-79013f82964553dfe4708d9a81a38ff965562b8c1f64707ee8fc9857aebc4e1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0016508501903269$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1132187$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11522742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Madsen, Karen</creatorcontrib><creatorcontrib>Cornish, Anthony</creatorcontrib><creatorcontrib>Soper, Paul</creatorcontrib><creatorcontrib>McKaigney, Conor</creatorcontrib><creatorcontrib>Jijon, Humberto</creatorcontrib><creatorcontrib>Yachimec, Christine</creatorcontrib><creatorcontrib>Doyle, Jason</creatorcontrib><creatorcontrib>Jewell, Lawrence</creatorcontrib><creatorcontrib>De Simone, Claudio</creatorcontrib><title>Probiotic bacteria enhance murine and human intestinal epithelial barrier function</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background & Aims: The probiotic compound, VSL#3, is efficacious as maintenance therapy in pouchitis and ulcerative colitis. The aim of this study was to determine the efficacy of VSL#3 as a primary therapy in the treatment of colitis in the interleukin (IL)-10 gene-deficient mouse. Mechanisms of action of VSL#3 were investigated in T84 monolayers. Methods: IL-10 gene-deficient and control mice received 2.8 × 108 colony-forming units per day of VSL#3 for 4 weeks. Colons were removed and analyzed for cytokine production, epithelial barrier function, and inflammation. VSL#3 or conditioned media was applied directly to T84 monolayers. Results: Treatment of IL-10 gene-deficient mice with VSL#3 resulted in normalization of colonic physiologic function and barrier integrity in conjunction with a reduction in mucosal secretion of tumor necrosis factor α and interferon γ and an improvement in histologic disease. In vitro studies showed that epithelial barrier function and resistance to Salmonella invasion could be enhanced by exposure to a proteinaceous soluble factor secreted by the bacteria found in the VSL#3 compound. Conclusions: Oral administration of VSL#3 was effective as primary therapy in IL-10 gene-deficient mice, and had a direct effect on epithelial barrier function.
GASTROENTEROLOGY 2001;121:580-591</description><subject>Animals</subject><subject>Bifidobacterium</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Colitis - metabolism</subject><subject>Colitis - therapy</subject><subject>Digestive system</subject><subject>Epithelial Cells - metabolism</subject><subject>Epithelial Cells - microbiology</subject><subject>Humans</subject><subject>Interleukin-10 - genetics</subject><subject>Interleukin-8 - metabolism</subject><subject>Intestinal Absorption - physiology</subject><subject>Intestinal Mucosa - cytology</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Intestinal Mucosa - microbiology</subject><subject>Lactobacillus</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Mice, Knockout</subject><subject>Patch-Clamp Techniques</subject><subject>Pharmacology. Drug treatments</subject><subject>Probiotics - pharmacology</subject><subject>Salmonella Infections - prevention & control</subject><subject>Salmonella Infections - therapy</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PwzAMQCMEYmNw5oZ6QNy6JWnTpEc08SVNAiE4R2nqsKA2HUmKxL8nY5PgwsmW_WzZD6FzgucEs2LxpkKcU4zJnHJKywM0JYyKPBXoIZqmUOUMCzZBJyG8Y4zrQpBjNCGJorykU_T85IfGDtHqrFE6grcqA7dWTkPWj946yJRrs_XYK5dZFyFE61SXwcbGNXQ2pY3y3oLPzOh0tIM7RUdGdQHO9nGGXm9vXpb3-erx7mF5vcp1yeuY8xqTwghaVyVjRWug5Fi0tRJEFcKYumKsoo3QxFSpwwGE0bVgXEGjS0jQDF3t9m788DGmw2Rvg4auUw6GMUievsRlJRK42IHaDyF4MHLjba_8lyRYbjXKrUa51Sh_NKaJi_3qsemh_eX33hJwuQdU0KozPgmz4Q9XUCJ4wuodBsnDZ5Ikg7aQ3LbWg46yHey_N3wDdmqOxQ</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>Madsen, Karen</creator><creator>Cornish, Anthony</creator><creator>Soper, Paul</creator><creator>McKaigney, Conor</creator><creator>Jijon, Humberto</creator><creator>Yachimec, Christine</creator><creator>Doyle, Jason</creator><creator>Jewell, Lawrence</creator><creator>De Simone, Claudio</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010901</creationdate><title>Probiotic bacteria enhance murine and human intestinal epithelial barrier function</title><author>Madsen, Karen ; Cornish, Anthony ; Soper, Paul ; McKaigney, Conor ; Jijon, Humberto ; Yachimec, Christine ; Doyle, Jason ; Jewell, Lawrence ; De Simone, Claudio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-79013f82964553dfe4708d9a81a38ff965562b8c1f64707ee8fc9857aebc4e1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Bifidobacterium</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Colitis - metabolism</topic><topic>Colitis - therapy</topic><topic>Digestive system</topic><topic>Epithelial Cells - metabolism</topic><topic>Epithelial Cells - microbiology</topic><topic>Humans</topic><topic>Interleukin-10 - genetics</topic><topic>Interleukin-8 - metabolism</topic><topic>Intestinal Absorption - physiology</topic><topic>Intestinal Mucosa - cytology</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Intestinal Mucosa - microbiology</topic><topic>Lactobacillus</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Mice, Knockout</topic><topic>Patch-Clamp Techniques</topic><topic>Pharmacology. Drug treatments</topic><topic>Probiotics - pharmacology</topic><topic>Salmonella Infections - prevention & control</topic><topic>Salmonella Infections - therapy</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Madsen, Karen</creatorcontrib><creatorcontrib>Cornish, Anthony</creatorcontrib><creatorcontrib>Soper, Paul</creatorcontrib><creatorcontrib>McKaigney, Conor</creatorcontrib><creatorcontrib>Jijon, Humberto</creatorcontrib><creatorcontrib>Yachimec, Christine</creatorcontrib><creatorcontrib>Doyle, Jason</creatorcontrib><creatorcontrib>Jewell, Lawrence</creatorcontrib><creatorcontrib>De Simone, Claudio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Madsen, Karen</au><au>Cornish, Anthony</au><au>Soper, Paul</au><au>McKaigney, Conor</au><au>Jijon, Humberto</au><au>Yachimec, Christine</au><au>Doyle, Jason</au><au>Jewell, Lawrence</au><au>De Simone, Claudio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotic bacteria enhance murine and human intestinal epithelial barrier function</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>121</volume><issue>3</issue><spage>580</spage><epage>591</epage><pages>580-591</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Background & Aims: The probiotic compound, VSL#3, is efficacious as maintenance therapy in pouchitis and ulcerative colitis. The aim of this study was to determine the efficacy of VSL#3 as a primary therapy in the treatment of colitis in the interleukin (IL)-10 gene-deficient mouse. Mechanisms of action of VSL#3 were investigated in T84 monolayers. Methods: IL-10 gene-deficient and control mice received 2.8 × 108 colony-forming units per day of VSL#3 for 4 weeks. Colons were removed and analyzed for cytokine production, epithelial barrier function, and inflammation. VSL#3 or conditioned media was applied directly to T84 monolayers. Results: Treatment of IL-10 gene-deficient mice with VSL#3 resulted in normalization of colonic physiologic function and barrier integrity in conjunction with a reduction in mucosal secretion of tumor necrosis factor α and interferon γ and an improvement in histologic disease. In vitro studies showed that epithelial barrier function and resistance to Salmonella invasion could be enhanced by exposure to a proteinaceous soluble factor secreted by the bacteria found in the VSL#3 compound. Conclusions: Oral administration of VSL#3 was effective as primary therapy in IL-10 gene-deficient mice, and had a direct effect on epithelial barrier function.
GASTROENTEROLOGY 2001;121:580-591</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11522742</pmid><doi>10.1053/gast.2001.27224</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0016-5085 |
ispartof | Gastroenterology (New York, N.Y. 1943), 2001-09, Vol.121 (3), p.580-591 |
issn | 0016-5085 1528-0012 |
language | eng |
recordid | cdi_proquest_miscellaneous_71150468 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection |
subjects | Animals Bifidobacterium Biological and medical sciences Cell Line Colitis - metabolism Colitis - therapy Digestive system Epithelial Cells - metabolism Epithelial Cells - microbiology Humans Interleukin-10 - genetics Interleukin-8 - metabolism Intestinal Absorption - physiology Intestinal Mucosa - cytology Intestinal Mucosa - metabolism Intestinal Mucosa - microbiology Lactobacillus Medical sciences Mice Mice, Inbred Strains Mice, Knockout Patch-Clamp Techniques Pharmacology. Drug treatments Probiotics - pharmacology Salmonella Infections - prevention & control Salmonella Infections - therapy Tumor Necrosis Factor-alpha - metabolism |
title | Probiotic bacteria enhance murine and human intestinal epithelial barrier function |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A32%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotic%20bacteria%20enhance%20murine%20and%20human%20intestinal%20epithelial%20barrier%20function&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Madsen,%20Karen&rft.date=2001-09-01&rft.volume=121&rft.issue=3&rft.spage=580&rft.epage=591&rft.pages=580-591&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1053/gast.2001.27224&rft_dat=%3Cproquest_cross%3E71150468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71150468&rft_id=info:pmid/11522742&rft_els_id=S0016508501903269&rfr_iscdi=true |